Cargando…

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaV...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yunlong, Yisimayi, Ayijiang, Bai, Yali, Huang, Weijin, Li, Xiaofeng, Zhang, Zhiying, Yuan, Tianjiao, An, Ran, Wang, Jing, Xiao, Tianhe, Du, Shuo, Ma, Wenping, Song, Liyang, Li, Yongzheng, Li, Xiang, Song, Weiliang, Wu, Jiajing, Liu, Shuo, Li, Xuemei, Zhang, Yonghong, Su, Bin, Guo, Xianghua, Wei, Yangyang, Gao, Chuanping, Zhang, Nana, Zhang, Yifei, Dou, Yang, Xu, Xiaoyu, Shi, Rui, Lu, Bai, Jin, Ronghua, Ma, Yingmin, Qin, Chengfeng, Wang, Youchun, Feng, Yingmei, Xiao, Junyu, Xie, Xiaoliang Sunney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138844/
https://www.ncbi.nlm.nih.gov/pubmed/34021265
http://dx.doi.org/10.1038/s41422-021-00514-9
_version_ 1783695888374300672
author Cao, Yunlong
Yisimayi, Ayijiang
Bai, Yali
Huang, Weijin
Li, Xiaofeng
Zhang, Zhiying
Yuan, Tianjiao
An, Ran
Wang, Jing
Xiao, Tianhe
Du, Shuo
Ma, Wenping
Song, Liyang
Li, Yongzheng
Li, Xiang
Song, Weiliang
Wu, Jiajing
Liu, Shuo
Li, Xuemei
Zhang, Yonghong
Su, Bin
Guo, Xianghua
Wei, Yangyang
Gao, Chuanping
Zhang, Nana
Zhang, Yifei
Dou, Yang
Xu, Xiaoyu
Shi, Rui
Lu, Bai
Jin, Ronghua
Ma, Yingmin
Qin, Chengfeng
Wang, Youchun
Feng, Yingmei
Xiao, Junyu
Xie, Xiaoliang Sunney
author_facet Cao, Yunlong
Yisimayi, Ayijiang
Bai, Yali
Huang, Weijin
Li, Xiaofeng
Zhang, Zhiying
Yuan, Tianjiao
An, Ran
Wang, Jing
Xiao, Tianhe
Du, Shuo
Ma, Wenping
Song, Liyang
Li, Yongzheng
Li, Xiang
Song, Weiliang
Wu, Jiajing
Liu, Shuo
Li, Xuemei
Zhang, Yonghong
Su, Bin
Guo, Xianghua
Wei, Yangyang
Gao, Chuanping
Zhang, Nana
Zhang, Yifei
Dou, Yang
Xu, Xiaoyu
Shi, Rui
Lu, Bai
Jin, Ronghua
Ma, Yingmin
Qin, Chengfeng
Wang, Youchun
Feng, Yingmei
Xiao, Junyu
Xie, Xiaoliang Sunney
author_sort Cao, Yunlong
collection PubMed
description SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents, near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination, with E484K being the dominant cause. VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants, and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions. In contrast, the 242–244 deletion (242–244Δ) would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite, indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs. Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo- and authentic 501Y.V2 variants, mainly caused by E484K/N501Y and 242–244Δ, with the effects being additive. Importantly, RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents, since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations. Moreover, an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration. Together, these results suggest that the deployment of RBD-vaccines, through a third-dose boost, may be ideal for combating SARS-CoV-2 variants when necessary, especially for those carrying mutations that disrupt the NTD supersite.
format Online
Article
Text
id pubmed-8138844
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-81388442021-05-21 Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines Cao, Yunlong Yisimayi, Ayijiang Bai, Yali Huang, Weijin Li, Xiaofeng Zhang, Zhiying Yuan, Tianjiao An, Ran Wang, Jing Xiao, Tianhe Du, Shuo Ma, Wenping Song, Liyang Li, Yongzheng Li, Xiang Song, Weiliang Wu, Jiajing Liu, Shuo Li, Xuemei Zhang, Yonghong Su, Bin Guo, Xianghua Wei, Yangyang Gao, Chuanping Zhang, Nana Zhang, Yifei Dou, Yang Xu, Xiaoyu Shi, Rui Lu, Bai Jin, Ronghua Ma, Yingmin Qin, Chengfeng Wang, Youchun Feng, Yingmei Xiao, Junyu Xie, Xiaoliang Sunney Cell Res Article SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents, near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination, with E484K being the dominant cause. VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants, and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions. In contrast, the 242–244 deletion (242–244Δ) would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite, indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs. Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo- and authentic 501Y.V2 variants, mainly caused by E484K/N501Y and 242–244Δ, with the effects being additive. Importantly, RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents, since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations. Moreover, an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration. Together, these results suggest that the deployment of RBD-vaccines, through a third-dose boost, may be ideal for combating SARS-CoV-2 variants when necessary, especially for those carrying mutations that disrupt the NTD supersite. Springer Singapore 2021-05-21 2021-07 /pmc/articles/PMC8138844/ /pubmed/34021265 http://dx.doi.org/10.1038/s41422-021-00514-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Cao, Yunlong
Yisimayi, Ayijiang
Bai, Yali
Huang, Weijin
Li, Xiaofeng
Zhang, Zhiying
Yuan, Tianjiao
An, Ran
Wang, Jing
Xiao, Tianhe
Du, Shuo
Ma, Wenping
Song, Liyang
Li, Yongzheng
Li, Xiang
Song, Weiliang
Wu, Jiajing
Liu, Shuo
Li, Xuemei
Zhang, Yonghong
Su, Bin
Guo, Xianghua
Wei, Yangyang
Gao, Chuanping
Zhang, Nana
Zhang, Yifei
Dou, Yang
Xu, Xiaoyu
Shi, Rui
Lu, Bai
Jin, Ronghua
Ma, Yingmin
Qin, Chengfeng
Wang, Youchun
Feng, Yingmei
Xiao, Junyu
Xie, Xiaoliang Sunney
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
title Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
title_full Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
title_fullStr Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
title_full_unstemmed Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
title_short Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
title_sort humoral immune response to circulating sars-cov-2 variants elicited by inactivated and rbd-subunit vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138844/
https://www.ncbi.nlm.nih.gov/pubmed/34021265
http://dx.doi.org/10.1038/s41422-021-00514-9
work_keys_str_mv AT caoyunlong humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT yisimayiayijiang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT baiyali humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT huangweijin humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT lixiaofeng humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT zhangzhiying humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT yuantianjiao humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT anran humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT wangjing humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT xiaotianhe humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT dushuo humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT mawenping humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT songliyang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT liyongzheng humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT lixiang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT songweiliang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT wujiajing humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT liushuo humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT lixuemei humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT zhangyonghong humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT subin humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT guoxianghua humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT weiyangyang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT gaochuanping humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT zhangnana humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT zhangyifei humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT douyang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT xuxiaoyu humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT shirui humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT lubai humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT jinronghua humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT mayingmin humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT qinchengfeng humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT wangyouchun humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT fengyingmei humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT xiaojunyu humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines
AT xiexiaoliangsunney humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines